Related Experiment Video
Updated: Aug 6, 2026

Immunolabelling Myofiber Degeneration in Muscle Biopsies
Published on: December 5, 2019
Muscleblind-like protein 1 nuclear sequestration is a molecular pathology marker of DM1 and DM2
R Cardani1, E Mancinelli, G Rotondo
1Department of Molecular Biology and Biotechnologies, University of Milan, Italy.
Abstract:
Myotonic dystrophies (DM) are repeat expansion diseases in which expanded CTG (DM1) and CCTG (DM2) repeats cause the disease. Mutant transcripts containing CUG/CCUG repeats are retained in muscle nuclei producing ribonuclear inclusions, which can bind specific RNA-binding proteins, leading to a reduction in their activity. The sequestration of muscleblind-like proteins (MBNLs), a family of alternative splicing factors, appears to be involved in splicing defects characteristic of DM pathologies. To determine whether MBNL1 nuclear sequestration is a feature of DM pathologies, we have examined the in vivo distribution of MBNL1 in muscle sections from genetically confirmed DM1 (n=7) and DM2 (n=9) patients, patients with other myotonic disorders (n=11) and from patients with disorders caused by repeat expansions, but not DM1/DM2 (n=3). The results of our immunofluorescence study indicate that, among patients examined, MBNL1 nuclear sequestration in protein foci is a molecular pathology marker of DM1 and DM2 patients where ribonuclear inclusions of transcripts with expanded CUG/CCUG repeats are also present. These findings indicate that MBNLs might be important targets for therapeutic interventions to correct some of the specific features of DM pathology.
Insights
Myotonic dystrophies (DM) are genetic disorders. This study found that MBNL1 protein sequestration in muscle nuclei is a key marker for DM1 and DM2, suggesting MBNLs as therapeutic targets.
Area of Science:
- Neurology
- Genetics
- Molecular Biology
Background:
- Myotonic dystrophies (DM) are repeat expansion disorders caused by expanded CTG (DM1) and CCTG (DM2) repeats.
- Mutant transcripts form ribonuclear inclusions in muscle nuclei, sequestering RNA-binding proteins like muscleblind-like proteins (MBNLs).
- MBNL sequestration is implicated in the splicing defects characteristic of DM.
Purpose of the Study:
- To investigate if MBNL1 nuclear sequestration is a pathological feature of DM.
- To identify molecular markers for DM1 and DM2.
Main Methods:
- Immunofluorescence study of MBNL1 distribution in muscle sections.
- Analysis of patients with genetically confirmed DM1, DM2, other myotonic disorders, and non-DM repeat expansion disorders.
Main Results:
- MBNL1 nuclear sequestration in protein foci was observed specifically in DM1 and DM2 patients.
- This sequestration correlated with the presence of ribonuclear inclusions containing expanded CUG/CCUG repeats.
- MBNL1 sequestration was not found in other myotonic disorders or non-DM repeat expansion disorders.
Conclusions:
- MBNL1 nuclear sequestration serves as a molecular pathology marker for DM1 and DM2.
- These findings highlight MBNLs as potential therapeutic targets for DM.
- Understanding MBNL sequestration is crucial for developing treatments for DM pathologies.
Related Concept Videos
Satellite Stem Cells and Muscular Dystrophy
Abnormal Proliferation
Alterations in Muscle Tone lll

